PacBio CFO Departs; New Directors Appointed

Ticker: PACB · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1299130

Sentiment: neutral

Topics: management-change, board-composition, cfo-departure

Related Tickers: PACB

TL;DR

PacBio CFO out, interim CFO in, two new board members added.

AI Summary

Pacific Biosciences of California, Inc. (PacBio) announced on March 24, 2025, the departure of its Chief Financial Officer, Christian O. Knutson, effective March 21, 2025. The company also announced the appointment of Sarah E. Johnson as interim CFO, effective March 21, 2025. Additionally, the company elected two new directors, Dr. Jonathan M. Rothberg and Dr. Richard K. King, to its Board of Directors.

Why It Matters

Changes in key financial and board leadership can signal strategic shifts or internal challenges, impacting investor confidence and the company's future direction.

Risk Assessment

Risk Level: medium — Changes in CFO and board composition can introduce uncertainty regarding financial strategy and corporate governance.

Key Players & Entities

FAQ

Who has been appointed as the interim Chief Financial Officer of Pacific Biosciences?

Sarah E. Johnson has been appointed as the interim Chief Financial Officer, effective March 21, 2025.

When did Christian O. Knutson's departure as CFO become effective?

Christian O. Knutson's departure as Chief Financial Officer was effective March 21, 2025.

Who are the new directors elected to the Board of Directors?

Dr. Jonathan M. Rothberg and Dr. Richard K. King have been elected as new directors.

What is the exact date of this Form 8-K filing?

The Form 8-K was filed on March 27, 2025, reporting events as of March 24, 2025.

What is the principal executive office address for Pacific Biosciences?

The principal executive offices are located at 1305 O'Brien Drive, Menlo Park, California 94025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 by Christian O. Knutson regarding PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing